The increased blood concentrations of leukocytes (which did not, however, exceed the leukocytosis level) in patients treated with Ca-antagonists seem to be a compensatory reaction against the increased number of leukocytes with the invalid MCP-1/CCR2 pathway. The gene discussed is CCR2; the disease is Increased total leukocyte count.